Stamp T C, Haddad J G, Twigg C A
Lancet. 1977 Jun 25;1(8026):1341-3. doi: 10.1016/s0140-6736(77)92553-3.
Circulating concentrations of 25-hydroxyvitamin D (25-OHD) were measured during short-term and long-term oral treatment with 25-hydroxycholecalciferol (25-OHD3), 25-H.C.C.) or with vitamin D in over 200 subjects over a period of 5 years. Ten times more vitamin D than 25-OHD3 was required to produce equivalent plasma-25-OHD concentrations. Plasma-25-OHD was a power function of dosage with both compounds. These data indirectly measure the superior therapeutic potency of 25-OHD3, show that dose-response relations with both compounds may be useful in diagnosis, and indicate that there are pronounced constraints on 25-hydroxylation of vitamin D. Together with the effects of ultraviolet light, now shown to be equivalent to oral vitamin D in doses of 8000-10 000 I.U. daily, these constraints may protect against vitamin-D deficiency in winter.
在超过200名受试者中,在5年的时间里,对他们进行了短期和长期口服25-羟胆钙化醇(25-OHD3,25-H.C.C.)或维生素D的治疗,并测量了循环中25-羟基维生素D(25-OHD)的浓度。要产生同等的血浆25-OHD浓度,所需的维生素D量是25-OHD3的10倍。血浆25-OHD是两种化合物剂量的幂函数。这些数据间接测量了25-OHD3的卓越治疗效力,表明两种化合物的剂量反应关系可能对诊断有用,并表明维生素D的25-羟化存在明显限制。再加上现在已证明紫外线的作用相当于每日8000 - 10000国际单位剂量的口服维生素D,这些限制可能有助于预防冬季维生素D缺乏。